Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Pharma giant AstraZeneca said a clinical trial of a drug to treat non-small cell lung cancer reduced the risk of disease recurrence or death by about 80%.
Detailed results from the Phase III ADAURA trial showed AstraZeneca's Tagrisso achieved its primary goal, and reduced the risk of disease recurrence or death by 83% in patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer.
At two years, 89% of patients in the trial treated with Tagrisso remained alive and disease free versus 53% on placebo, the company said.
At 8:09am: (LON:AZN) Astrazeneca PLC share price was +245.5p at 8943.5p